Table 2.
Results of the unadjusted and multivariable cause-specific, time-dependent Cox models studying the risk of basal cell carcinoma (n=2473)
| Exposure | Unadjusted | Adjusted | ||
|---|---|---|---|---|
| Hazard Ratio | 95% Confidence Interval | Hazard Ratio | 95% Confidence Interval | |
| HTCZ exposure | 0.79 | [0.45 to 1.40] | 0.63 | [0.35 to 1.15] |
| Recipient age | 1.05 | [1.04 to 1.07] | 1.05 | [1.04 to 1.07] |
| Men | 1.39 | [0.99 to 1.95] | 1.52 | [1.04 to 2.23] |
| Initial nephropathy | ||||
| Chronic tubulointerstitial nephritis/ADPKD/congenital uropathy (versus glomerulopathy) | 1.22 | [0.83 to 1.77] | 1.25 | [0.84 to 1.86] |
| Diabetes (versus glomerulopathy) | 0.53 | [0.29 to 0.96] | 0.72 | [0.31 to 1.63] |
| Other (versus glomerulopathy) | 0.81 | [0.42 to 1.57] | 0.65 | [0.33 to 1.28] |
| Vascular nephropathy (versus glomerulopathy) | 1.94 | [1.09 to 3.46] | 1.07 | [0.57 to 2.01] |
| KRT | — | — | ||
| Hemodialysis (versus preemptive transplantation) | 0.96 | [0.63 to 1.47] | — | — |
| Peritoneal dialysis (versus preemptive transplantation) | 1.51 | [0.80 to 2.86] | — | — |
| Kidney transplantation | 2.93 | [1.44 to 5.94] | 1.80 | [0.60 to 5.40] |
| Retransplantation | 1.09 | [0.73 to 1.64] | 1.04 | [0.59 to 1.81] |
| Deceased donor | 1.03 | [0.62 to 1.71] | 0.97 | [0.54 to 1.72] |
| HLA-A -B -Dr mismatches ≥4 | 0.86 | [0.63 to 1.19] | 0.87 | [0.62 to 1.24] |
| Cold ischemia time ≥18 h | 0.74 | [0.54 to 1.02] | 0.56 | [0.39 to 0.80] |
| Delayed graft function | 0.96 | [0.68 to 1.36] | — | — |
| Rejection | 0.71 | [0.36 to 1.40] | 0.89 | [0.45 to 1.73] |
| Other malignancies | 0.89 | [0.39 to 2.04] | 0.38 | [0.16 to 0.94] |
| Induction treatment | ||||
| Nondepleting (versus depleting) | 1.11 | [0.80 to 1.53] | 0.79 | [0.51 to 1.23] |
| None (versus depleting) | 1.09 | [0.45 to 2.60] | 0.99 | [0.41 to 2.43] |
| Calcineurin inhibitors | ||||
| Cyclosporin (versus tacrolimus) | 1.13 | [0.79 to 1.61] | 1.31 | [0.88 to 1.93] |
| None (versus tacrolimus) | 0.67 | [0.16 to 2.76] | 0.68 | [0.14 to 3.26] |
| Steroid-free regimen | 1.03 | [0.71 to 1.49] | 0.98 | [0.66 to 1.46] |
| Calcineurin inhibitors during follow-up | 0.46 | [0.32 to 0.67] | 0.49 | [0.28 to 0.85] |
| mTOR inhibitors during follow-up | 1.87 | [1.19 to 2.92] | 1.01 | [0.54 to 1.88] |
| Mycophenolate derivatives during follow-up | 0.68 | [0.46 to 0.99] | 0.88 | [0.58 to 1.34] |
HCTZ, hydrochlorothiazide; ADPKD, autosomal dominant polycystic kidney disease; —, not available; HLA, human leucocyte antigen; mTOR, mammalian target of rapamycin.